Clinical Biological and Pharmacological Factors Influencing Stroke Outcome
biostroke
Characterization of Clinical, Biological and Pharmacological Markers of Stroke Outcome
2 other identifiers
observational
550
1 country
1
Brief Summary
In a previous suty, we have demonstrated that prior transient ischemic attack, treatment lipid-lowering drug or physical activity are associated to a better outcome of stroke. The aim of the study is to understand the mechanisms of this preventive neuroprotection by establishing link between biomarkers and preventive and neuroprotective measures.To answer to the question, we conduct a cohort study of stroke patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2005
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 26, 2008
CompletedFirst Posted
Study publicly available on registry
September 30, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2012
CompletedMay 13, 2015
May 1, 2015
4 years
September 26, 2008
May 12, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
severity of stroke measured by NIH severity score
inclusion, day7, month3, year3
Secondary Outcomes (1)
clinical, pharmacological and biological (metabolic, inflammation, hemostasis...) cognitive status
inclusion and year3
Study Arms (1)
stroke patient cohort
Patients with an hemispheric ischemic or hemorrhage stroke hospitalized during the 48h following the beginning of stroke
Eligibility Criteria
Cohort of stroke patient
You may qualify if:
- ischemic or hemorrhage stroke
- hemispheric stroke
- stroke dating from less 48h
You may not qualify if:
- non hemispheric stroke
- malformative intracranial hemorrhage
- traumatic intracranial hemorrhage
- subarachnoidal hemorrhage
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Lille University Hospital - Service de Neurologie vasculaire
Lille, France
Related Publications (2)
Colin O, Labreuche J, Deguil J, Mendyk AM, Deken V, Cordonnier C, Deplanque D, Leys D, Bordet R. Preadmission use of benzodiazepines and stroke outcomes: the Biostroke prospective cohort study. BMJ Open. 2019 Jan 15;9(1):e022720. doi: 10.1136/bmjopen-2018-022720.
PMID: 30782684DERIVEDMoulin S, Leys D, Schraen-Maschke S, Bombois S, Mendyk AM, Muhr-Tailleux A, Cordonnier C, Buee L, Pasquier F, Bordet R. Abeta1-40 and Abeta1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics. Curr Alzheimer Res. 2017;14(6):686-694. doi: 10.2174/1567205012666151027141730.
PMID: 26502812DERIVED
Biospecimen
whole blood and serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
regis BORDET, MD,PhD
Lille University Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 26, 2008
First Posted
September 30, 2008
Study Start
June 1, 2005
Primary Completion
June 1, 2009
Study Completion
June 1, 2012
Last Updated
May 13, 2015
Record last verified: 2015-05